Making Opioid Drugs Less Alluring Congress should act to

New Post Public Reply Private Reply Replies (0) Message Board

Jan 19, 2013 at 2:20 PM

Making Opioid Drugs Less Alluring
Congress should act to continue the manufacture of tamper-resistant pills.
By LYNN WEBSTER
January 13, 2013

New York Mayor Michael Bloomberg announced last week that the city's emergency rooms will begin restricting patients to a three-day supply of opioid painkillers. The move is meant to counter rampant abuse of OxyContin and other drugs, often by addicts who get pills from family members or friends who receive more than they need from doctors. The Centers for Disease Control and Prevention estimates that 15,000 Americans die annually from opioids, either in suicides or accidental overdoses by addicts and non-addicts.

Given that opioids used in prescription drugs are a mainstay of treatment for millions of Americans with moderate-to-severe pain, how can the drugs be made safer? Part of the answer has to do with formulations of the drugs that are designed to slowly release them over eight, 12 or 24 hours. Although an extended release has therapeutic value in many situations, until recently the pills could be crushed, making all of the opioid effective immediately and giving abusers the euphoria they sought.

The positive news is that now there are products with tamper-resistant features that make extended-release medication far more difficult to convert to an immediate, full dose of the drug. It is still early, but preliminary reports show that tamper-resistant opioids are less likely to be abused.

The Food and Drug Administration has already proposed that manufacturers be required to cooperate to educate all of the nation's more than 350,000 physicians on how to reduce the potential abuse and lethality of extended-release opioids.

But there is a major hitch. Just as it appears that industry has made some progress, albeit small, toward safer opioid formulations, patents are ending on drugs with tamper-resistant formulas—specifically Purdue's OxyContin and Endo's Opana. If the FDA and Congress fail to act, generic versions of extended-release drugs in their original formulations—without a tamper-resistance formula—are due to hit the market in early 2013.

If easily abusable formulations are made available again, why should users seeking a high not turn to them? Furthermore, what incentives will spur opioid makers to continue to formulate safer products?

Here is where Congress comes in. The Stop Tampering of Prescription Pills Act would prevent generics from being approved that are copies of older, more abuse-prone formulations. In effect, the Stopp Act would sidestep a Catch-22 that now confounds makers of tamper-resistant, extended-release opioids. When the companies developed the new versions, the manufacturers could not legally claim that the new formulas were tamper-resistant—because they had not yet met rigorous and time-consuming FDA testing requirements to prove that claim. Instead the makers of extended-release oxymorphone and oxycodone products simply replaced earlier versions of the medications with the new tamper-resistant ones.

The FDA's rule that reformulated products cannot carry labeling claims of tamper resistance until they have been on the market long enough to be sufficiently studied—plus a lack of clarity on what scientific standards tamper-resistant products must meet—is what allows generics to argue that their products are equivalent. Consider the possible harmful result when insurance companies and government payers inevitably place generics on a less-expensive tier than brand-name products, ensuring that patients and doctors are forced via pricing to use less-safe medications. The Stopp Act was designed to avoid these sorts of dilemmas, while helping prescribers differentiate the potential safety of the varying formulations.

Some argue that pharmaceutical companies wish only to safeguard their profits in blocking generics from issuing earlier, non-tamper-resistant formulations. Maybe so—but what is the alternative? Allow recreational abuse and addictive behaviors to shift to the "old school" opioids with no attendant responsibility placed on the generic manufacturers?

The makers of certain extended-release opioids have risen to the call for safer formulations. There is wisdom in expecting makers of generics to abide by the same rules of safety.

With the power to relieve pain comes the danger of ending life if medications are improperly consumed or prescribed. Congress has before it a clear path that likely will prevent innumerable deaths. I hope lawmakers will take it.

Dr. Webster is president-elect of the American Academy of Pain Medicine and medical director of CRILifetree in Salt Lake City.

Elite Pharmaceuticals Inc (ELTP) Stock Research Links

ELTP Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SVRN Taps Industry Vet Patrick O'Kain as COO

SVRN Aims for New Heights with a Savvy Hire If there’s one thing veteran market-watchers like myself know, it’s that leadership shifts can tell you more about a company’s guts than any press release. SVRN (NASDAQ: SVRN), a name with one foot firmly in the world of digital assets, just snagged Patrick O’Kain for their COO spot. They're not playing around, folks,...

Annual Home Insurance Check: Paul Bernieri's Top Tips

Don't Sleep on Your Annual Insurance Review Ever feel like insurance policy reviews are one of those boring chores? Well, Paul Bernieri would probably say they're anything but. In a recent HelloNation article, our favorite insurance expert, Paul Bernieri from Garden City, NY, dissects the crucial areas homeowners on Long Island need to examine each year. It's basically a...

CVS Health Boosts 2026 Guidance Amid Revenue Jump

A Solid Quarter for CVS Health CVS Health Corporation has once again turned heads with its third-quarter 2026 results. When you're pulling $108.4 billion in quarterly revenue, up 5.4% from last year, folks notice. Adjusted earnings hit $2.09 per share, climbing a respectable 30% from $1.60 the year before. The cherry on top? A big fat boost in 2026 guidance, signaling...

NACCO Navigates Strong 2026 Q3, Faces Solar Cost Hurdles

Rolling With NACCO's Financial Punches Well, folks, when it rains, it pours—numbers that is. NACCO Industries just laid out their Q3 results for all to gawk at, and it's a mixed bag of triumphs and tussles. You got a gross profit of $11.8 million, a sweet 18% jump on the same quarter last year. Now, you're talking about revenue muscle, and there it is. Income before...

WellNet Embraces Voice AI for Provider Calls

Ever met a TPA grappling over their provider call costs like a crusty sailor with a rusted anchor? Welcome to WellNet Healthcare, folks. They've tapped EHVAhealth's conversational voice AI to take a solid swing at automating those burdensome provider calls. They're no stranger to the chaos of managing member eligibility and benefits verification, and this move might just...

KFC Teams with Marvel for Record-Breaking Menu Launch

Movie Magic on the Menu When was the last time a bucket of fried chicken sent such ripple effects through pop culture? KFC's decision to sling Doctor Doom-inspired dishes across 100 countries smells like genius business mixed with a dash of the absurd. Just imagine: an empire of battered birds aligning with Marvel's latest cinematic heavy hitter, "Avengers: Doomsday." Now...

Everest Group Faces Shaky Ground in Securities Fraud Suit

Investors Take Aim at Everest Group's Alleged Missteps Looks like Everest Group, Ltd. (NYSE: EG) has found itself knee-deep in legal quicksand. There's a class-action lawsuit afoot, spearheaded by the folks at Schall, Brown & Schwartz LLP. They're putting forward claims that Everest, a player in the securities exchange, was painting a misleading picture when it came to...

Zillow Eases the FHA Down Payment Burden

A New Financial Lifeline for Homebuyers In a market where finding a foothold in the housing game feels like scaling Everest without ropes, Zillow Home Loans has tossed a lifeline to potential homeowners. Their latest move might just be what many house hunters needed to hear—offering a hand where it’s been missing for years: down payment assistance for FHA loans. The...

Life with PAH: A Journey of Awareness and Hope

Unearthing the Hidden Struggle of PAH The American Lung Association (ALA) is getting loud about a quiet killer—pulmonary arterial hypertension (PAH) is in their spotlight this month, and it's about time. Documenting the horror stories of some 500 to 1,000 new PAH diagnoses each year in the U.S., the ALA is peeling back the blinds on a condition that's too often...

Systemair Wins First Natural Refrigerant Heat Pump Deal

Systemair Breaks New Ground Hold onto your hats, because Systemair just sealed a deal that's going to make waves. Their recent accomplishment isn't just some humdrum business tedium—it's an intriguing step forward in the HVAC world. Systemair snagged their very first order for air handling units featuring an integrated heat pump and natural refrigerant. You've got to...